Mixed amylin activity compounds
View Patent ↗Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.
1. A compound of the formula:
X 1 -X 2 -X 3 -Leu-X 4 -Glu-Leu-X 5 -X 6 -Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-X 7 -Z 3 [SEQ.ID.NO.27]
wherein:
(a) X 1 is
(i) a group of two amino acid residues selected from the group consisting of Leu-Leu, Val-Leu, Ile-Leu, tert-Leu-Leu, Nle-Leu, and Ala-Thr, and N-acylated derivatives thereof; or
(ii) the group Z 1 -Ser-Thr-Z 2 -Val-Leu [SEQ.ID.NO. 28] wherein Z 1 is an amino acid residue selected from the group consisting of Leu, Val, Ile, tert-Leu, Nva, Abu, and Nle or an N-acylated derivative thereof or Z 1 is an alkanoyl group; and Z 2 is a amino acid residue selected from the group consisting of Ala, Ser, Cys, and Thr;
(b) X 2 is an amino acid residue selected from the group consisting of Gly, Glu, Asn or Aib;
(c) X 3 is an amino acid residue selected from the group consisting of Arg, Orn, Lys and ε-amidated derivatives thereof;
(d) X 4 is a group of two amino acid residues selected from the group consisting of Ser-Gln, Thr-Gln, Ala-Asn and Thr-Asn;
(e) X 5 is an amino acid residue selected from the group consisting of His, Aib, Ile, Leu and Val;
(f) X 6 is an amino acid residue selected from the group consisting of Arg, Orn and Lys and ε-amidated derivatives thereof;
(g) X 7 is a group having 6 amino acid residues selected from the group consisting of
(i) Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 29];
(ii) Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 30];
(iii) Val-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 31];
(iv) Val-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 32]; and
(h) Z a is OH or NH 2 ;
with the proviso that the compound does not have the formula of any of SEQ. ID. NOS. 14 to 26; and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1 wherein Z 3 is NH 2 .
3. A compound according to claim 1 wherein X 2 is Gly.
4. A compound according to claim 3 wherein X 5 is His or Aib.
5. A compound according to claim 4 wherein X 4 is Ser-Gln.
6. A compound according to claim 5 wherein X 7 is Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 29] or Thr-Gly-Ser-Gly-Thr-Pro-NH 2 [SEQ.ID.NO. 30].
7. A compound according to claim 6 wherein X 1 is Z 1 -Ser-Thr-Z 2 -Val-Leu [SEQ.ID.NO.28].
8. A compound according to claim 7 wherein X 3 and X 6 are ε-amidated with a carboxylic acid having 1 to 8 carbon atoms.
9. A compound according to claim 1 wherein Z 1 is an alkanoyl group having 1 to about 10 carbon atoms or Leu.
10. A compound according to claim 9 wherein Z 2 is Ala or Cys.
11. A compound according to claim 10 wherein Z 1 is an alkanoyl group.
12. A compound according to claim 11 wherein X 3 and X 6 are formamidated or acetamidated.
13. A compound according to claim 12 wherein Z 2 is Ala.
14. A compound according to claim 13 wherein X 3 and X 6 are Lys(For).
15. A compound according to claim 14 wherein Z 1 is 4-methylpentanoyl.
16. A compound according to claim 1 which has an amino acid sequence selected from the group consisting of:
Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 1];
4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 2];
Ac-Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 3];
Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 4];
Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 5];
Ac-Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 6];
Ac-Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 7];
Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Gl-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 8];
Ac-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 9];
4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 10];
4-methylpentanoyl-Ser-Thr-Cys-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 11];
Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 12];
and
Ac-Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 13].
17. The compound Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 1].
18. The compound 4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 2].
19. A composition comprising a compound of any of claims 1 to 8 in a pharmaceutically acceptable carrier.
20. A method of treating diabetes in a subject in need of treatment which comprises administering to said subject a therapeutically effective amount of a compound of any of claim 1 , 2 , 15 , 16 , 17 or 18 .
21. A method according to claim 20 wherein said diabetes is type I diabetes.
22. A method according to claim 20 wherein said diabetes is type II diabetes.
23. A method of beneficially regulating gastrointestinal motility in a subject comprising administering to said subject a therapeutically effective amount of a compound of any of claim 1 , 2 , 15 , 16 , 17 or 18 .
24. A method according to claim 23 wherein said beneficial regulation of gastrointestinal motility comprises delaying gastric emptying.
25. A method of treating a disorder selected from the group consisting of: impaired glucose tolerance; postprandial hyperglycemia; obesity; and Syndrome x; in a subject in need of treatment which comprises administering to said subject a therapeutically effective amount of a compound of any of claim 1 , 2 , 15 , 16 , 17 or 18 .